Non-Surgical Joint Care Solutions in Baltimore, MD

non surgical joint care for a city of 500k–1M — without a fake storefront

If a sales sheet cannot tell you that Baltimore is JL (Novitas Solutions) and that adult diabetes here is 14.4% (PLACES 2023), it is selling units, not a program. That is the non surgical joint care conversation we actually have.

The chart problems we still see in MD

• Adult arthritis here is 25% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 10.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Maryland.
• Pressure-injury and DFU programs in any city of 585,708 still fail on offloading and bioburden before they fail on product. Biologics are adjuncts — Novitas Solutions reviewers look for that sequence.
• Maryland is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

Why we will not invent a Baltimore diabetes rate

10.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. A city of 500k–1M with 585,708 residents will still mix those payers. CDC PLACES (2023, crude) estimates 14.4% of adults in Baltimore have diagnosed diabetes — 2.4 points above the U.S. 12% figure. Build two utilization policies if you do both cash PRP and Medicare CTPs.

Do this before you expand SKUs